Question & Answer Article

Cardiovascular Toxicity of Immune Checkpoint Inhibitors

Emanuel Raschi¹, Simone Rossi^{2,3}, Andrea De Giglio^{1,4}, Michele Fusaroli¹, Flavio Burgazzi¹, Rita Rinaldi²,

Luciano Potena⁵

¹ Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy

² IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

³ Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum - University of

Bologna, Bologna, Italy.

⁴ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

⁵ Unit of Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna,

Italy.

Correspondence:

Emanuel Raschi, MD, PhD

Pharmacology Unit - Department of Medical and Surgical Sciences

Alma Mater Studiorum - University of Bologna

Via Irnerio 48, 40126, Bologna, Italy

Phone: +39 051 2091802

e-mail: emanuel.raschi@unibo.it

ORCID: 0000-0003-0487-7996

Electronic Supplementary Material

Methods for article selection

Date of search	December 20 th , 2022
Database search	Medline-Pubmed
Search criteria	Combinations of keywords (immune checkpoint inhibitors, checkpoint
	inhibitors, checkpoint blockade, cardiotoxicity, cardiovascular toxicity, cardio-
	oncology, myocarditis)
Inclusion criteria	Articles in humans dealing with cardiovascular toxicity with immune checkpoint
	inhibitors (epidemiology, diagnosis, assessment, surveillance, management).
	Both original and review articles were considered.
	Review articles were used for snowballing.
Exclusion criteria	Articles not in English
Criteria to prioritize	Guidelines by major scientific societies (ESC, ASCO, ESMO, NCCN, SITC).
pertinent articles	Articles published in major cardiological (NEJM, Lancet, Circulation, JACC, JACC
	CardioOncology, EHJ) and oncology Journals (Lancet Oncology, JAMA Oncology,
	JCO, Ann Oncol, EJC, Journal for Immunotherapy of Cancer).
	Articles published in the last 5 years.